There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSV), Abeona Therapeutics (ABEO) and Synlogic Inc (SYBX) with bullish sentiments.
ObsEva SA (OBSV)
Wedbush analyst Liana Moussatos reiterated a Buy rating on ObsEva SA yesterday and set a price target of $37. The company’s shares closed yesterday at $13.90.
According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -8.7% and a 33.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ObsEva SA with a $33.40 average price target, implying a 140.3% upside from current levels. In a report issued on April 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $44 price target.
See today’s analyst top recommended stocks >>
Abeona Therapeutics (ABEO)
Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Abeona Therapeutics yesterday and set a price target of $29. The company’s shares closed yesterday at $7.70, close to its 52-week low of $6.26.
Piros noted:
“: We are reiterating our OW rating and $29 12-month price target on Abeona. The company had one oral presentation and two poster presentations at ASGCT, which we are attending. Abeona is creating a portfolio of earlier stage programs that have differentiated mechanisms, across numerous indications (lungs, CNS, ocular).”
According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.0% and a 46.0% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abeona Therapeutics with a $25 average price target, representing a 224.7% upside. In a report issued on April 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $30 price target.
Synlogic Inc (SYBX)
In a report released yesterday, Taylor Feehley from Chardan Capital reiterated a Buy rating on Synlogic Inc, with a price target of $20. The company’s shares closed yesterday at $8.58.
Feehley said:
“We were also impressed by the reduction of free DNA, free protein, and free endotoxin (to a lesser extent) in the solid preparation, which may help to improve tolerability (Figure 7). The batch-to-batch consistency plus stability at both 2-8ºC and room temperature of the solid formulation are also key features of this new process.”
According to TipRanks.com, Feehley is a 1-star analyst with an average return of -0.4% and a 54.5% success rate. Feehley covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Kaleido Biosciences Inc, and Evelo Biosciences Inc.
Currently, the analyst consensus on Synlogic Inc is a Strong Buy with an average price target of $20, a 133.1% upside from current levels. In a report released yesterday, Jefferies also initiated coverage with a Buy rating on the stock with a $18 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
